Alnylam Pharmaceuticals

Alnylam issued U.S. patent broadly covering RNAi therapeutics

Published in Healthcare Finance, Tax and Law Weekly, July 5th, 2006

Alnylam Pharmaceuticals, Inc., (ALNY) announced that a key fundamental patent from its exclusively held "Tuschl II" patent series was issued by the United States Patent and Trademark Office (USPTO).

The U.S. patent (U.S. Patent No. 7,056,704) broadly covers methods of making small interfering RNAs (siRNAs), the molecules that mediate RNAi. The issued patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Garching Innovation GmbH, the licensing agent for the Max Planck Society.

The new patent stems from groundbreaking research published in 2001 in the journal Nature by Thomas Tuschl, PhD, a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2006-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry